Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?

@article{Soga1999IsAP,
  title={Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?},
  author={T Soga and Minoru Matsuura and Yuzo Kodama and Tsuyoshi Fujita and Ikufumi Sekimoto and K Nishimura and Syunichi Yoshida and Hiromu Kutsumi and Sotaro Fujimoto},
  journal={Journal of Gastroenterology},
  year={1999},
  volume={34},
  pages={435-440}
}
Abstract: The efficacy of histamine H2 receptor antagonist (H2RA) and proton pump inhibitor (PPI) therapies in healing reflux esophagitis was compared in a prospective randomized case-control comparative study. A total of 71 patients with grade A to D esophagitis (Los Angeles classification) were given either famotidine 20 mg twice a day (Fam; n = 35) or omeprazole 20 mg once daily (Ome; n = 36) for 8 weeks. Endoscopy was performed to assess healing in 57 patients. Healed patients were followed… Expand
[Therapeutic effect of low-dose omeprazole vs. standard-dose ranitidine in mild to moderate reflux esophagitis].
TLDR
The low-dose omeprazole therapy produced similar healing rates and safety in the treatment of MMRE, and L-OMP is advantageous in its once-a-day dosing and might be an alternative to S-H2RA, especially in Korean patients with MMRE. Expand
Comparative Study of a Proton Pump Inhibitor with a Histamine H2?Receptor Antagonist in Japanese Patients with Functional Dyspepsia
TLDR
The PPI and H2RA produced a comparable improvement in symptoms of FD in the authors' patient cohort, thus it is proposed no advantage would be gained in using a PPI rather than an H2 RA. Expand
Evaluation of symptomatic reflux esophagitis in proton pump inhibitor users
TLDR
A younger age and HH were associated with symptomatic RE in patients with RE who were administered PPIs, investigated in a hospital-based, retrospective cross-sectional study of consecutive RE cases in PPI users recruited between 2008 and 2016. Expand
Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.
TLDR
H(2)RAs are less effective for treating patients with erosive esophagitis, especially in those with severe forms of esophageal cancer, and standard dose proton pump inhibitors given at the recommended dose are equally effective for healing esphagitis. Expand
Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A
TLDR
Proton pump inhibitors produced consistently greater healing rates than H2RAs of all doses across all grades of esophagitis, including patients refractory to H1N1, as well as similar healing rates achieved with standard dose omeprazole. Expand
Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia
The aim of the present study was to investigate the efficacy of a potassium-competitive acid blocker (PCAB) named vonoprazan (VPZ) for improving symptoms in patients with reflux esophagitis (RE),Expand
Beyond acid suppressants in gastro-oesophageal reflux disease
TLDR
Evidence is presented that a novel antioxidant substance (DA-9601) significantly attenuates the severity of oesophageal inflammation in a rat model of oESophagitis, and it is demonstrated that DA- 9601 was more effective in the prevention of oedema than physiological concentrations of ranitidine. Expand
Review: Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia
TLDR
In patients with reflux esophagitis, dose escalation and co-administration with a histamine H2-receptor antagonist are potential approaches, since the major cause of PPI resistance is incomplete suppression of gastric acid secretion. Expand
The early therapeutic response at 2 weeks is a crucial predictor of proton pump inhibitor-refractory gastroesophageal reflux disease
TLDR
Medication change for PPI-refractory GERD at 2 weeks may be an efficacious therapeutic strategy to improve patients’ quality of life. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 16 REFERENCES
Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice.
TLDR
This study has shown that 10 mg omeprazole once daily is an effective and well-tolerated treatment strategy in general practice for the long-term management of symptoms of GORD in patients without erosive oesophagitis. Expand
Comparison of omeprazole and famotidine on esophageal pH in patients with moderate to severe esophagitis: a cross-over study.
TLDR
O was superior to F, but the latter drug improved significantly two important prognostic variables: the total percent of time pH < 4 and the nocturnal GER. Expand
Healing and relapse of severe peptic esophagitis after treatment with omeprazole.
TLDR
Omeprazole is a highly effective treatment for peptic esophagitis, and the 40-mg/day dosage produces endoscopic healing slightly more quickly than the 20-mg/, and the initial endoscopic gradings are of prognostic value. Expand
Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis.
TLDR
Both drugs significantly reduced esophageal exposure to acid in both the supine and upright positions and higher-than-presently-recommended doses of H2-blockers, whereas neither had any effect on esophagal acid clearance. Expand
The role and limitations of H2‐receptor antagonist in the treatment of gastro‐oesophageal refrux disease
TLDR
More prolonged suppression of acid secretion, such as by a histamine H2‐receptor antagonist (H2RA) or a proton pump inhibitor (PPI) is required to give long‐lasting symptomatic relief and heal any inflammatory change. Expand
Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations.
TLDR
Omeprazole healed a greater proportion of patients with reflux oesophagitis than cimetidine, assessed endoscopically and histologically, and relieved more patients' symptoms. Expand
Efficacy of omeprazole in lower grades of gastro-oesophageal reflux disease.
TLDR
The results show that the differences in efficacy between omeprazole and H2-receptor antagonists, which have been established for the treatment of erosive and ulcerative oesophagitis, also extend to patients with grade I oesphagitis (erythema and friability). Expand
Indications for HP eradication: gastro-esophageal reflux disease.
TLDR
The possible acceleration of atrophic gastritis development in HP positive patients using strong acid secretion inhibitors is the strongest argument in favour of eradicating HP in patients receiving long term potent acid inhibition, especially GERD patients. Expand
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication.
TLDR
Patients with reflux esophagitis and H. pylori infection who are treated with omeprazole are at increased risk of atrophic gastritis. Expand
Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.
TLDR
Omeprazole 30 mg/day is the optimal dose for a maximal decrease of 24 hour intragastric acidity in duodenal ulcer patients, with full recovery seven weeks later. Expand
...
1
2
...